Potential utility of natural polyphenols for reversing fat-induced insulin resistance.
There is intriguing recent evidence that the beta subunit of the signalsome--IKKbeta, a crucial catalyst of NF-kappaB activation--is an obligate mediator of the disruption of insulin signaling induced by excessive exposure of tissues to free fatty acids and by hypertrophy of adipocytes. Thus, agents which safely inhibit or suppress the activation of IKKbeta may have utility for reversing insulin resistance syndrome and aiding control of type 2 diabetes. Two natural agents which can achieve this effect in vitro--and which may have clinical potential in this regard--are the polyphenols resveratrol and silibinin. To date, limited absorbability and/or rapid glucuronidation have prevented these agents from achieving full therapeutic utility, but, by administering these agents in optimally absorbable forms, and co-administering inhibitors of glucuronidation such as probenecid, it may prove feasible to make these agents more clinically viable. Oral silibinin, in the guise of the milk thistle extract silymarin, already has documented clinical utility in a range of hepatic disorders, and recent evidence that dietary silibinin can inhibit the growth of certain cancers in rodents suggests that this agent may indeed have clinical potential as an IKKbeta inhibitor. A report that silymarin has a favorable impact on glycemic and lipidemic control in type 2 diabetics with cirrhosis, may or may not be indicative of IKKbeta inhibition in skeletal muscle and adipocytes. In light of the fact that IKKbeta plays a crucial role, not only in the induction of insulin resistance, but also atherogenesis, a host of inflammatory disorders, and the survival and spread of cancer, the development of pharmaceutical agents that could safely and feasibly achieve a down-regulation of IKKbeta activity would have broad therapeutic and preventive implications.
McCarty
Mark F
MF
Pantox Laboratories, 4622 Santa Fe St., San Diego, CA 92109, USA. mccarty@pantox.com
D017667:Adipocytes / Q000378:metabolism; D003924:Diabetes Mellitus, Type 2 / Q000517:prevention & control; D005230:Fatty Acids, Nonesterified / Q000378:metabolism*; D005419:Flavonoids / Q000378:metabolism*; D006801:Humans; D051550:I-kappa B Kinase; D007333:Insulin Resistance; D008954:Models, Biological; D010636:Phenols / Q000378:metabolism*; D059808:Polyphenols; D011339:Probenecid / Q000627:therapeutic use; D017346:Protein Serine-Threonine Kinases / Q000378:metabolism; D000077185:Resveratrol; D000077385:Silybin; D012838:Silymarin / Q000378:metabolism; D013267:Stilbenes / Q000378:metabolism
D005230:Fatty Acids, Nonesterified; D005419:Flavonoids; D010636:Phenols; D059808:Polyphenols; D012838:Silymarin; D013267:Stilbenes; D000077385:Silybin; D017346:Protein Serine-Threonine Kinases; C496559:CHUK protein, human; D051550:I-kappa B Kinase; C496560:IKBKB protein, human; C496565:IKBKE protein, human; D011339:Probenecid; D000077185:Resveratrol